Side-by-Side Comparison
| Metric | DeepCure | Pharvaris |
|---|---|---|
| Founded | ||
| Founded | 2018 | 2015 older |
| Headquarters | ||
| Headquarters | Boston, United States | Zug, Switzerland |
| Employees | ||
| Employees | 28 | 139 larger |
| Industry | ||
| Industry | AI, Biotechnology, Machine Learning | Biotechnology, Health Care, Life Sciences |
| Funding Stage | ||
| Funding Stage | Series A | IPO |
| Total Funding | ||
| Total Funding | $64.60M | $967.33M |
| Funding Rounds | ||
| Funding Rounds | 5 | 8 |
| Services | ||
| Services | Development of small molecule therapies, Research and development of STAT6 inhibitors, Collaboration with academic and research institutions | Development of oral bradykinin B2 receptor antagonists, Research and clinical trials for hereditary and acquired angioedema, Providing oral alternatives to traditional injection therapies |
| Target Customers | ||
| Target Customers | Pharmaceutical companies, Biotech firms, Healthcare providers, Medical researchers, Patients with immune diseases | Patients with hereditary angioedema (HAE), Patients with acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), Healthcare providers managing bradykinin-mediated conditions |
| Taxonomy | ||
| Taxonomy | Small Molecule Therapies, Immune Diseases, Inflammatory Diseases, AI-Driven Drug Discovery, Novel Molecules, Drug Discovery Platform, Oral STAT6 Program, Selective Inhibitors, BRD4(BD2) Program, Precision Therapeutics, Unmet Medical Needs, Chemistry Innovation, Advanced Physics Tools, Immunology Solutions, Pharmaceutical Development | Clinical-stage Biotechnology, Bradykinin-B2-Receptor Antagonists, Oral Therapeutics Development, Rare Disorders, Hereditary Angioedema, Small Molecule Drug Discovery, Pharmaceutical Development, Novel Therapeutics, Phase 1 Clinical Trials, Drug Candidate Development, Innovative Medicine, Receptor-mediated Diseases, Non-injectable Therapies, Biotech Leadership |
| Website | ||
| Website | deepcure.com | pharvaris.com |
About DeepCure
DeepCure, founded in 2018 and headquartered in the United States, is innovating the landscape of small molecule therapies specifically targeting immune and inflammatory diseases. The company's slogan, "Reimagining small molecule therapies for immune diseases," encapsulates its mission to introduce g...
About Pharvaris
Pharvaris, founded in 2015, is a Switzerland-based clinical-stage company at the forefront of developing oral treatments for bradykinin-mediated diseases such as hereditary angioedema (HAE). The company’s slogan, "Pioneering science for patient choice", reflects its dedication to innovative therapeu...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at DeepCure and Pharvaris — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at DeepCure and Pharvaris — by email.
Frequently Asked Questions
Compare DeepCure with someone else
Start typing a company name or domain.